Cargando…
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Multiple myeloma is the second most common hematological malignancy. Despite significant advances in treatment, relapse is common and carries a poor prognosis. Thus, it is critical to elucidate the genetic factors contributing to disease progression and drug resistance. Here, we carry out integrativ...
Autores principales: | Vo, Josh N., Wu, Yi-Mi, Mishler, Jeanmarie, Hall, Sarah, Mannan, Rahul, Wang, Lisha, Ning, Yu, Zhou, Jin, Hopkins, Alexander C., Estill, James C., Chan, Wallace K. B., Yesil, Jennifer, Cao, Xuhong, Rao, Arvind, Tsodikov, Alexander, Talpaz, Moshe, Cole, Craig E., Ye, Jing C., Bergsagel, P. Leif, Auclair, Daniel, Cho, Hearn Jay, Robinson, Dan R., Chinnaiyan, Arul M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243087/ https://www.ncbi.nlm.nih.gov/pubmed/35768438 http://dx.doi.org/10.1038/s41467-022-31430-0 |
Ejemplares similares
-
Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant
por: Meermeier, Erin W., et al.
Publicado: (2023) -
Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022) -
UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression
por: Hussain, Sajjad, et al.
Publicado: (2015) -
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
por: Davies, Faith E., et al.
Publicado: (2022) -
Frequent occurrence of large duplications at reciprocal genomic rearrangement breakpoints in multiple myeloma and other tumors
por: Demchenko, Yulia, et al.
Publicado: (2016)